JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Essman, S. C.
Right arrow Articles by Kuroki, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Essman, S. C.
Right arrow Articles by Kuroki, K.
Journal of Nuclear Medicine Vol. 44 No. 9 1510-1515
© 2003 by Society of Nuclear Medicine


Basic Science Investigations

Effects of 153Sm-Ethylenediaminetetramethylene Phosphonate on Physeal and Articular Cartilage in Juvenile Rabbits

Stephanie C. Essman, DVM1, Jim Lattimer, DVM1, James L. Cook, DVM, PhD2, Sue Turnquist, DVM, PhD3 and Keiichi Kuroki, DVM2

1 Department of Medicine and Surgery, University of Missouri-Columbia, Columbia, Missouri
2 Comparative Orthopaedic Laboratory, University of Missouri-Columbia, Columbia, Missouri
3 Department of Pathobiology, University of Missouri-Columbia, Columbia, Missouri

Previous studies reported that the radiopharmaceutical 153Sm-ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) is an effective component of multimodality therapy for the treatment of primary bone tumors. Therefore, 153Sm-EDTMP may prove to be an integral component of therapy for the treatment of juvenile osteosarcoma. The purpose of this study was to determine the effects of intravenous administration of 153Sm-EDTMP on the developing physeal and articular cartilage of healthy, juvenile rabbits. Methods: Sixteen healthy 8-wk-old male New Zealand White rabbits were assigned to 1 of 2 groups: treatment (n = 12) and control (n = 4). 153Sm-EDTMP was administered to the treatment group at 37 MBq/kg (1 mCi/kg). The animals were sacrificed at 16 wk of age, and the physeal cartilage of multiple bones was evaluated by use of histologic, immunohistochemical, and histomorphometric analyses. The overall changes in the lengths of the radius and the tibia between control and treatment groups were calculated and compared. Measurement data were combined for each group, and means ± SEMs were determined. Results: Significant differences in radial bone growth were present between the groups. Histologically, the physes of the treatment group were disrupted and chaotic in appearance. Significant differences in the immunoreactivity of type X collagen and matrix metalloproteinase-13 were seen between the groups, as these markers were positively expressed in the zone of hypertrophy of the control rabbits. Conclusion: Clinically significant damage to the developing physeal cartilage may occur as a result of the intravenous administration of 153Sm-EDTMP at the dose studied.

Key Words: growth • 153Sm-ethylenediaminetetramethylene phosphonate • osteosarcoma • physis • rabbit







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.